YTS109 cell therapy for severe autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Kidney & urinary, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of the autoimmune diseases listed in the trial (like lupus with kidney problems or low platelets, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, or antiphospholipid syndrome).
- Your disease has not responded to or has come back after trying at least two standard treatments (such as steroids, cyclophosphamide, or newer biologics).
- Your overall health is good enough for the study, with adequate liver, kidney, bone marrow, and heart function.
- You are not pregnant, and you agree to use effective birth control during and for 12 months after the treatment.
- You do not have active infections, recent blood clots, cancer in the last 5 years, or other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial tests a new cell therapy called SNC116 for people with lupus that has not improved with standard treatments. The treatment aims to reset the immune system to reduce disease activity and may help those with severe lupus or kidney inflammation.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.